Awada A - Search Results

1

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A. Kourie HR, et al. Among authors: awada a. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57. doi: 10.1080/17425255.2016.1198317. Epub 2016 Jun 27. Expert Opin Drug Metab Toxicol. 2016. PMID: 27284682 Review.

2

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

de Valeriola D, Awada A, Roy JA, Di Leo A, Biganzoli L, Piccart M. de Valeriola D, et al. Among authors: awada a. Drugs. 1997 Sep;54(3):385-413. doi: 10.2165/00003495-199754030-00003. Drugs. 1997. PMID: 9279502 Review.

3

State-of-the-art chemotherapy for advanced breast cancer.

Piccart MJ, Awada A. Piccart MJ, et al. Among authors: awada a. Semin Oncol. 2000 Oct;27(5 Suppl 9):3-12. Semin Oncol. 2000. PMID: 11049051 Review.

4

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, Hamilton A, Nooij M, Piccart M. Awada A, et al. Eur J Cancer. 2002 Apr;38(6):773-8. doi: 10.1016/s0959-8049(01)00427-0. Eur J Cancer. 2002. PMID: 11937310 Clinical Trial.

5

The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions.

Ferreira Filho AF, Di Leo A, Paesmans M, Beauduin M, Vindevoghel A, Michel J, Focan C, Awada A, Cardoso F, Dolci S, Bartholomeus S, Piccart MJ. Ferreira Filho AF, et al. Among authors: awada a. Ann Oncol. 2002 Mar;13(3):416-21. doi: 10.1093/annonc/mdf051. Ann Oncol. 2002. PMID: 11996473 Free article. Clinical Trial.

6

New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.

Awada A. Awada A. Forum (Genova). 2002;12(1):4-15. Forum (Genova). 2002. PMID: 12634907 Review.

7

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

Atalay G, Cardoso F, Awada A, Piccart MJ. Atalay G, et al. Among authors: awada a. Ann Oncol. 2003 Sep;14(9):1346-63. doi: 10.1093/annonc/mdg365. Ann Oncol. 2003. PMID: 12954573 Free article. Review.

8

The pipeline of new anticancer agents for breast cancer treatment in 2003.

Awada A, Cardoso F, Atalay G, Giuliani R, Mano M, Piccart MJ. Awada A, et al. Crit Rev Oncol Hematol. 2003 Oct;48(1):45-63. doi: 10.1016/s1040-8428(03)00171-9. Crit Rev Oncol Hematol. 2003. PMID: 14585483 Review.

9

New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.

Awada A, Mano M, Hendlisz A, Piccart M. Awada A, et al. Expert Rev Anticancer Ther. 2004 Feb;4(1):53-60. doi: 10.1586/14737140.4.1.53. Expert Rev Anticancer Ther. 2004. PMID: 14748657 Review.

10

Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.

Mano MS, Awada A, Minisini A, Durbecq V, Di Leo A, Piccart M. Mano MS, et al. Among authors: awada a. Breast. 2004 Aug;13(4):347-9. doi: 10.1016/j.breast.2003.11.009. Breast. 2004. PMID: 15325672

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

557 results

Search Page

Filters